Advertisement

Virchows Archiv

, Volume 467, Issue 3, pp 357–363 | Cite as

BCR–ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR

  • Antonella Zagaria
  • Luisa Anelli
  • Nicoletta Coccaro
  • Giuseppina Tota
  • Paola Casieri
  • Angelo Cellamare
  • Luciana Impera
  • Claudia Brunetti
  • Angela Minervini
  • Crescenzio Francesco Minervini
  • Mario Delia
  • Cosimo Cumbo
  • Paola Orsini
  • Giorgina Specchia
  • Francesco Albano
Case Report

Abstract

The BCR–ABL1 fusion on the Philadelphia (Ph) chromosome is a hallmark of chronic myeloid leukemia (CML). More than 95 % of BCRABL1 transcripts in CML are either e13a2 or e14a2 (major breakpoint cluster region or M-bcr), whereas rare BCR–ABL1 transcripts are occasionally observed, accounting for less than 1 % of CML cases. Among these, a very rare fusion transcript joining the first 6 exons of BCR to exon 2 of ABL1 (e6a2) has been reported in various hematological malignancies characterized by an aggressive clinical course. We report a new case of blast crisis (BC) CML with an e6a2 fusion transcript characterized by many eosinophil precursors with abnormal granules. Moreover, fluorescence in situ hybridization analysis revealed genomic deletions of 1.3 megabases and 342 kilobases on der(9) of chromosome 9 and 22 sequences, respectively. The fusion transcript was quantified at diagnosis and during follow-up using digital droplet polymerase chain reaction (ddPCR) technology. The patient was treated with Dasatinib (140 mg/day), resulting in a 3-log reduction of the e6a2 transcript molecular burden from the third month after treatment. In this twentieth e6a2 case, characterized by marked eosinophilic dysplasia, deletions on der(9), and responsive to tyrosine kinase inhibitors therapy, we demonstrate that for molecular response monitoring of rare fusion transcripts associated with CML, ddPCR is a very useful technology.

Keywords

Chronic myeloid leukemia BCRABL1 e6a2 transcript Digital droplet polymerase chain reaction Eosinophilic dysplasia Genomic microdeletions 

Notes

Acknowledgments

The authors would like to thank Ms. MVC Pragnell, B.A., for language revision of the manuscript.

This work was supported by “Fondazione Cassa di Risparmio di Puglia” and “Associazione Italiana contro le Leucemie (AIL)-BARI”.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethics statement

This study was performed in agreement with the Declaration of Helsinki and approved by the local Ethical Committee (Comitato Etico Indipendente Locale, Azienda Ospedaliera “Ospedale Policlinico Consorziale” di Bari, Regione Puglia). Written informed consent was obtained from the patient; a copy of written consents is available for review by the Editor of this journal.

References

  1. 1.
    Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356PubMedGoogle Scholar
  2. 2.
    Ravandi F, Kebriaei P (2009) Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23:1043–1063PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Keung YK, Beaty M, Powell BL, Molnar I, Buss D, Pettenati M (2004) Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 28:579–586CrossRefPubMedGoogle Scholar
  4. 4.
    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951CrossRefPubMedGoogle Scholar
  5. 5.
    Chiarella P, Summa V, De Santis S, Signori E, Picardi E, Pesole G, Saglio G, Fazio VM (2012) BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias. Curr Mol Med 12:547–565CrossRefPubMedGoogle Scholar
  6. 6.
    Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H, Mey UJ, Eucker J, Rieder H, Gökbuget N, Hoelzer D, Thiel E (2007) Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica 92:1699–1702CrossRefPubMedGoogle Scholar
  7. 7.
    Ritchie DS, McBean M, Westerman DA, Kovalenko S, Seymour JF, Dobrovic A (2008) Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. Blood 111:2896–2898CrossRefPubMedGoogle Scholar
  8. 8.
    Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B (2007) Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia 21:2376–2377CrossRefPubMedGoogle Scholar
  9. 9.
    Grégoire MJ, Latger-Cannard V, Staal A, Bologna S, Leotard B, Rault JP, Béry-Dexheimer M, Jonveaux P (2006) Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript. Acta Haematol 116:216–218CrossRefPubMedGoogle Scholar
  10. 10.
    Rohon P, Divoka M, Calabkova L, Mojzikova R, Katrincsakova B, Rusinakova Z, Lapcikova A, Raida L, Faber E, Jarosova M, Divoky V, Indrak K (2011) Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155:187–190CrossRefPubMedGoogle Scholar
  11. 11.
    Beel KA, Lemmens J, Vranckx H, Maertens J, Vandenberghe P (2011) CML with e6a2 BCR-ABL1 transcript: an aggressive entity? Ann Hematol 90:1241–1243CrossRefPubMedGoogle Scholar
  12. 12.
    Langabeer SE, Crampe M, Kelly J, Fadalla K, Connaghan G, Conneally E (2010) Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts. Leuk Res 34:e204–e205CrossRefPubMedGoogle Scholar
  13. 13.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P (2009) Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Acta Haematol 122:11–16CrossRefPubMedGoogle Scholar
  14. 14.
    Schnittger S, Bacher U, Kern W, Haferlach T, Hertenstein B, Haferlach C (2008) A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment. Leukemia 22:856–858CrossRefPubMedGoogle Scholar
  15. 15.
    Breccia M, Cannella L, Diverio D, Streponi P, Nanni M, Stefanizzi C, Natalino F, Mecarocci S, Alimena G (2008) Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib. Leuk Res 32:177–180CrossRefPubMedGoogle Scholar
  16. 16.
    Torres F, Ivanova-Dragoeva A, Pereira M, Veiga J, Rodrigues AS, Sousa AB, Tavares P, Fernandes AR (2007) An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation. Leuk Lymphoma 48:1034–1037CrossRefPubMedGoogle Scholar
  17. 17.
    Popovici C, Cailleres S, David M, Lafage-Pochitaloff M, Sainty D, Mozziconacci MJ (2005) E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to imatinib. Leuk Lymphoma 46:1375–1377CrossRefPubMedGoogle Scholar
  18. 18.
    Roti G, La Starza R, Gorello P, Gottardi E, Crescenzi B, Martelli MF, Mecucci C (2005) e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia. Haematologica 90:1139–1141PubMedGoogle Scholar
  19. 19.
    Hayette S, Tigaud I, Thomas X, French M, Perrin MC, Nicolini F, Michallet M, Magaud JP (2004) Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report. Leukemia 18:1735–1736CrossRefPubMedGoogle Scholar
  20. 20.
    Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N (2004) e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease? Haematologica 89:611–613PubMedGoogle Scholar
  21. 21.
    Schultheis B, Wang L, Clark RE, Melo JV (2003) BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. Leukemia 17:2054–2055CrossRefPubMedGoogle Scholar
  22. 22.
    Dupont M, Jourdan E, Chiesa J (2000) Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML. Leukemia 14:2011–2012CrossRefPubMedGoogle Scholar
  23. 23.
    Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC (1996) A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236–2240PubMedGoogle Scholar
  24. 24.
    van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diáz MG, Malec M, Langerak AW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 13:1901–1928CrossRefPubMedGoogle Scholar
  25. 25.
    Shaffer LG, Slovak ML, Campbell LJ (2009) ISCN 2009 an international system for human cytogenetic nomenclature. Karger, BaselGoogle Scholar
  26. 26.
    Lichter P, Tang Chang CJ, Call K, Hermanson G, Evans GA, Housman D, Ward DC (1990) High-resolution mapping of human chromosome 11 by in situ hybridization with cosmid clones. Science 247:64–69CrossRefPubMedGoogle Scholar
  27. 27.
    Wongboonma W, Thongnoppakhun W, Auewarakul CU (2011) A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients. J Hematol Oncol 4:7PubMedCentralPubMedGoogle Scholar
  28. 28.
    Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA (1992) Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13:444–449PubMedGoogle Scholar
  29. 29.
    Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 10:1003–1005PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe against cancer program. Leukemia 17:2318–2357CrossRefPubMedGoogle Scholar
  31. 31.
    Albano F, Anelli L, Zagaria A, Archidiacono N, Liso V, Specchia G, Rocchi M (2007) “Home-brew” FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia. Cancer Genet Cytogenet 174:121–126CrossRefPubMedGoogle Scholar
  32. 32.
    Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, Eaves CJ (2015) Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood 125:504–515PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Laurent E, Talpaz M, Kantarjian H, Kurzrock R (2001) The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 61:2343–2345PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Antonella Zagaria
    • 1
  • Luisa Anelli
    • 1
  • Nicoletta Coccaro
    • 1
  • Giuseppina Tota
    • 1
  • Paola Casieri
    • 1
  • Angelo Cellamare
    • 1
  • Luciana Impera
    • 1
  • Claudia Brunetti
    • 1
  • Angela Minervini
    • 1
  • Crescenzio Francesco Minervini
    • 1
  • Mario Delia
    • 1
  • Cosimo Cumbo
    • 1
  • Paola Orsini
    • 1
  • Giorgina Specchia
    • 1
  • Francesco Albano
    • 1
  1. 1.Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology SectionUniversity of BariBariItaly

Personalised recommendations